This question tests knowledge of antibiotic safety during pregnancy, specifically first-trimester contraindications. The patient is 10 weeks pregnant with uncomplicated cystitis requiring antibiotic therapy. Trimethoprim/sulfamethoxazole (choice D) is contraindicated in the first trimester due to trimethoprim's antifolate activity, which increases the risk of neural tube defects and other congenital anomalies. Nitrofurantoin (choice A) is safe after the first trimester but should be used with caution in early pregnancy. Cephalexin (choice B) is a pregnancy category B antibiotic and represents the safest choice for this patient. Fosfomycin (choice C) has limited pregnancy data but is generally considered safe. The clinical pearl is that folate antagonists like trimethoprim should be avoided in the first trimester, and beta-lactam antibiotics like cephalexin are preferred for UTI treatment during pregnancy.

This question tests recognition of benzodiazepine precautions in patients with respiratory compromise. The patient has COPD requiring home oxygen, indicating severe respiratory impairment, and is prescribed diazepam 10 mg three times daily, which is a high dose of a long-acting benzodiazepine. The primary concern (choice A) is respiratory depression and excessive sedation, as benzodiazepines depress the respiratory drive and can precipitate respiratory failure in COPD patients, especially at high doses in elderly patients. Choice B incorrectly suggests INR monitoring, which isn't relevant to diazepam. Choice C about potassium supplementation and choice D about grapefruit juice interactions are not applicable to benzodiazepines. The clinical pearl is that benzodiazepines should be used with extreme caution in COPD patients, starting with the lowest effective dose of shorter-acting agents, and avoiding long-acting benzodiazepines like diazepam when possible.

This question tests contraindications for antibiotics in patients on QT-prolonging antiarrhythmics. The key patient-specific factor is the patient's dofetilide therapy for atrial fibrillation, which increases torsades de pointes risk. Trimethoprim-sulfamethoxazole is contraindicated because it can prolong the QT interval, potentiating arrhythmias with dofetilide. Doxycycline, amoxicillin-clavulanate, and cefpodoxime do not significantly affect QT. These options are acceptable alternatives post-allergy consideration. A pearl is to review QT risks before prescribing in arrhythmia patients, following AHA guidelines. Emphasize avoiding additive QT-prolonging agents to mitigate cardiac events.

This question assesses contraindications for antidiabetic agents based on family history. The key patient-specific factor is the family history of medullary thyroid carcinoma, raising concerns for C-cell tumors. Semaglutide is contraindicated or should be avoided because GLP-1 agonists carry a boxed warning for thyroid C-cell tumors in patients with personal or family history of MTC or MEN2. Empagliflozin, sitagliptin, and pioglitazone lack this risk. The distractors are appropriate for glycemic control. A pearl is to screen for MTC history before GLP-1 initiation, following ADA guidelines. Decision-making should include genetic risk assessment to avoid promoting rare malignancies.

This question tests drug interactions between antibiotics and mood stabilizers in urinary tract infection treatment. The key patient-specific factor is the patient's lithium therapy for bipolar disorder, which can lead to toxicity with certain drugs. Trimethoprim-sulfamethoxazole is contraindicated due to its potential to decrease lithium clearance, increasing toxicity risk per interaction data. Nitrofurantoin, ciprofloxacin, and fosfomycin lack significant lithium interactions. These options are suboptimal only if resistance is present but not contraindicated. A pearl is to check for interactions with narrow therapeutic index drugs like lithium, following psychiatric guidelines. Decision-making should prioritize avoiding combinations that alter renal handling of lithium.

This question evaluates NSAID contraindications in patients with cardiovascular and renal disease. The patient has heart failure with reduced ejection fraction, CKD stage 3a, and is on multiple medications that affect renal function and potassium levels, with a current potassium of 5.1 mEq/L (upper limit of normal). Ibuprofen (choice C) is contraindicated due to multiple factors: NSAIDs worsen heart failure by promoting sodium and water retention, reduce renal function in CKD patients, and can cause hyperkalemia, especially when combined with ACE inhibitors/ARBs and potassium-sparing diuretics like spironolactone. Topical diclofenac (choice A) has minimal systemic absorption and is safer. Acetaminophen (choice B) lacks these cardiovascular and renal effects. Intra-articular corticosteroids (choice D) provide local relief without systemic NSAID exposure. The key principle is that oral NSAIDs are contraindicated in heart failure and should be avoided in CKD patients on RAAS inhibitors due to cumulative risks.

This question evaluates the appropriate dosing adjustment of colchicine in severe renal impairment. The patient has an eGFR of 18 mL/min/1.73 m², indicating severe renal impairment (CKD stage 4), which significantly reduces colchicine clearance and increases toxicity risk. The correct adjustment (choice C) is to reduce colchicine to a single 0.6 mg dose without repeating for at least 2 weeks, as recommended by FDA guidelines for severe renal impairment. Choice A is incorrect because normal hepatic function doesn't negate the need for renal adjustment. Choice B incorrectly suggests using allopurinol for acute flares, when it's only for chronic management. Choice D dangerously suggests increasing the dose when reduction is needed. The key principle is that colchicine requires significant dose reduction in severe renal impairment due to decreased clearance and increased risk of life-threatening toxicity.

This question tests contraindications for analgesics in patients on monoamine oxidase inhibitors. The key patient-specific factor is the patient's phenelzine (MAOI) therapy, increasing serotonin syndrome risk. Tramadol is contraindicated because its serotonergic effects combined with MAOIs can precipitate serotonin syndrome, including agitation and hyperthermia. Acetaminophen, topical diclofenac, and naproxen lack serotonergic activity. The distractors are safer for pain management. A pearl is to avoid serotonergic agents within 14 days of MAOIs, per psychiatric guidelines. Decision frameworks should include interaction screening to prevent neurologic crises.

This question evaluates contraindications for cough suppressants in patients with urinary retention risks. The key patient-specific factor is the patient's benign prostatic hyperplasia with urinary retention episodes, exacerbated by anticholinergics. Diphenhydramine is contraindicated because its anticholinergic effects can worsen urinary retention and cause acute complications. Dextromethorphan lacks anticholinergic activity; guaifenesin is an expectorant without retention risks; honey is a non-pharmacologic option. The distractors are safer alternatives without similar side effects. A pearl is to assess for BPH before recommending anticholinergic OTCs, per urology guidelines. Emphasize guideline-based selection of agents with minimal anticholinergic burden in elderly or at-risk males.

This question assesses bleeding risk contraindications for OTC analgesics in anticoagulated patients. The key patient-specific factor is the patient's warfarin therapy with elevated INR 3.1, heightening hemorrhage potential. Ibuprofen is contraindicated or should be avoided because NSAIDs inhibit platelet function and increase bleeding risk with anticoagulants. Acetaminophen is safer at limited doses; topical menthol/methyl salicylate has lower systemic effects; heat therapy is non-pharmacologic. The distractors pose less bleeding threat. A pearl is to monitor INR with any analgesic addition, following anticoagulation guidelines. Emphasize selecting low-risk options to maintain therapeutic INR without complications.